Tolerability, Pharmacokinetics, and Serum Bactericidal Activity of Intravenous Dalbavancin in Healthy Volunteers

Author:

Leighton Anton1,Gottlieb Alice Bendix2,Dorr Mary Beth1,Jabes Daniela3,Mosconi Giorgio3,VanSaders Claudia2,Mroszczak Edward J.1,Campbell Kathleen C. M.4,Kelly Ellen5

Affiliation:

1. Vicuron Pharmaceuticals, Inc., King of Prussia, Pennsylvania 19406

2. Clinical Research Center, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey 08903

3. Vicuron Pharmaceuticals, 21040 Gerenzano (Varese), Italy

4. Southern Illinois University School of Medicine, Springfield, Illinois 62794

5. Center for Speech and Hearing Sciences, East Brunswick, New Jersey 08816

Abstract

ABSTRACT Fifty-two healthy adult male and female volunteers were enrolled in this double-blind study to determine the maximum tolerated dose, characterize the pharmacokinetics, and obtain serum bactericidal activity (SBA) data for intravenous dalbavancin. Subjects were assigned to single- or multiple-dose groups and randomized to receive dalbavancin or placebo intravenously over 30 min. Doses started at 140 mg in the single-dose group and with a 300-mg loading dose (LD), followed by six daily 30-mg maintenance doses (MDs), in the multiple-dose cohort and escalated to a 1,120-mg single dose and a 1,000-mg LD and 100-mg MD regimen. Plasma, urine, and skin blister fluid aspirate drug concentrations were measured, and pharmacokinetic parameters were determined via noncompartmental methods. SBA against methicillin-resistant Staphylococcus aureus (MRSA) was determined at several time points. Adverse events and changes from the baseline for laboratory data, electrocardiograms, audiologic assessments, physical examinations, and vital signs were assessed. Concentrations increased in proportion to the dose. Steady-state concentrations were achieved by day 3 with the 10:1 LD-MD regimen. The half-life averaged 181 h, and the mean volume of distribution and clearance were 9.75 liters and 0.0473 liters/h, respectively. Mean values were similar in all groups and in males and females. The portion of the dose excreted renally averaged 33.5%. Bactericidal activity was demonstrated in serum at 7 days in all subjects receiving single doses of ≥500 mg. All doses were well tolerated. Dose-limiting toxicity was not encountered. No changes in auditory or vestibular function occurred. The long half-life and maintenance of SBA against MRSA for 1 week suggest that weekly dosing may be feasible.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference14 articles.

1. American Speech-Language Hearing Association. 1994. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. Am. Speech-Lang. Hear. Assoc.36:11-19.

2. Campbell, K. C. M., E. Kelly, and N. Targovnik, L. Hughes, C. Van Saders, A. B. Gottlieb, M. B. Dorr, and A. Leighton. 2003. Audiologic monitoring for potential ototoxicity in a phase 1 clinical trial of a new glycopeptide antibiotic. J. Am. Acad. Audiol.14:157-168.

3. Candiani, G., M. Abbondi, M. Borgonovi, G. Romanò, and F. Parenti. 1999. In vitro and in vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J. Antimicrob. Chemother.44:179-192.

4. Diekema, D. J., M. A. Pfaller, R. N. Jones, G. V. Doern, K. C. Kuegler, M. L. Beach, H. S. Sader, and The SENTRY Participants Group. 2002. Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America: report from the SENTRY Antimicrobial Surveillance Programme, 1998. Int. J. Antimicrob. Agents13:257-271.

5. In Vitro Activities of Dalbavancin and Nine Comparator Agents against Anaerobic Gram-Positive Species and Corynebacteria

Cited by 167 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3